Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. Common Stock
Your view on NMRA
Overview
What the company does, where it operates, and who runs it.
About Neumora Therapeutics, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daljit Singh Aurora
- Headquarters
- 490 Arsenal Way, Watertown, DE, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daljit Singh Aurora
- Headquarters
- 490 Arsenal Way, Watertown, DE, US
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Neumora Therapeutics, Inc. Common Stock from FRC's valuation model, read against the market price. NMRA last traded at $0.37; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Neumora Therapeutics, Inc. Common Stock. Starting points for Neumora Therapeutics, Inc. Common Stock: EPS -$1.03, beta 3.14 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Neumora Therapeutics, Inc. Common Stock. Neumora Therapeutics, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Neumora Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Neumora Therapeutics, Inc. Common Stock stands at -$1.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$5.67
average of 3 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy6
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.17 | -$0.13 | -$0.89 | -$0.57 |
| Low estimate | -$0.19 | -$0.14 | -$0.96 | -$0.73 |
| High estimate | -$0.14 | -$0.12 | -$0.69 | -$0.32 |
| No. of analysts | 4 | 2 | 5 | 6 |
| Year-ago EPS | -$0.35 | -$0.30 | -$1.45 | — |
| Growth | +50.7% | +56.0% | +38.4% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $16000.00 | $16000.00 | $625000.00 | $2.90M |
| Low estimate | $16000.00 | $16000.00 | $625000.00 | $2.90M |
| High estimate | $16000.00 | $16000.00 | $625000.00 | $2.90M |
| No. of analysts | 1 | 1 | 8 | 5 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 17, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Neumora Therapeutics, Inc. Common Stock. Neumora Therapeutics, Inc. Common Stock has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ADCTADC Therapeutics S.A.Biotechnology$160M
- ALMSAlumis Inc. Common StockBiotechnology$665M
- AUTLAutolus Therapeutics plcBiotechnology$303M
- BCYCBicycle Therapeutics plcBiotechnology$223M
- FDMT4D Molecular Therapeutics, Inc.Biotechnology$624M
- FULCFulcrum Therapeutics, Inc.Biotechnology$283M
- LXRXLexicon Pharmaceuticals, Inc.Biotechnology$779M
- OMEROmeros CorporationBiotechnology$1.2B
More Biotechnology companies
- MIRMMirum Pharmaceuticals, Inc.NASDAQ$6.0B
- MISTMilestone Pharmaceuticals Inc.NASDAQ$45M
- MLECMoolec Science S.A.NASDAQ$617,200
- MLECWMoolec Science S.A.NASDAQ$76,243
- MLLCFMolecular Partners AGOTC$131M
- MLTXMoonLake ImmunotherapeuticsNASDAQ$998M
- MLYSMineralys Therapeutics, Inc.NASDAQ$1.3B
- MMIRFMedMira Inc.OTC$9M
- MNKDMannKind CorporationNASDAQ$1.3B
- MNOVMediciNova, Inc.NASDAQ$69M
- MNPRMonopar Therapeutics Inc.NASDAQ$488M
- MOLNMolecular Partners AGNASDAQ$103M
ETFs holding Neumora Therapeutics, Inc. Common Stock
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- IWMiShares Russell 2000 ETF$76.6B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- IWOiShares Russell 2000 Growth ETF$13.7B in assets0.00%
- VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
- PRFZInvesco RAFI US 1500 Small-Mid ETF$2.6B in assets0.00%
- SMMDiShares Russell 2500 ETF$4.1B in assets0.00%
- VHTVanguard Health Care ETF$19.1B in assets0.00%
Largest holders first, then the funds most concentrated in NMRA.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Neumora Therapeutics, Inc. Common Stock, and how their positions are changing. At a $69.4M market value, institutional positions materially move Neumora Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Neumora Therapeutics, Inc. Common Stock executives and directors. Shares of Neumora Therapeutics, Inc. Common Stock have traded between $0.61 and $11.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Neumora Therapeutics, Inc. Common Stock. Coverage tracks Neumora Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Neumora Therapeutics, Inc. Common Stock.